GeneDx Holdings (WGS) Capital Expenditures (2020 - 2026)

GeneDx Holdings (WGS) has reported Capital Expenditures for 7 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 3.49% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at -$214000.0 (down 102.58% YoY), while the FY2024 annual figure was $2.6 million, up 1838.06% from the prior year.
• Capital Expenditures improved to $5.9 million in Q1 2026 per WGS's latest filing, from -$14.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $6.2 million in Q3 2025 and bottomed at -$14.7 million in Q4 2025.
• Historically, Capital Expenditures has averaged $987625.0 across 5 years, with a median of $1.4 million in 2022.
• On a YoY basis, Capital Expenditures climbed as much as 3984.48% in 2025 and fell as far as 97700.0% in 2025.
• GeneDx Holdings' Capital Expenditures stood at $5.6 million in 2022, then tumbled by 119.36% to -$1.1 million in 2023, then soared by 98.62% to -$15000.0 in 2024, then sank by 97700.0% to -$14.7 million in 2025, then jumped by 140.32% to $5.9 million in 2026.
• Business Quant data shows WGS's Capital Expenditures at $5.9 million in Q1 2026, -$14.7 million in Q4 2025, and $6.2 million in Q3 2025.